慢性乙型肝炎治疗的研究进展  

Research Progress in the Treatment of Chronic Hepatitis B

作　　者：谢华 何良梅 刘瑶[2] 张自翔[2] XIE Hua;HE Liang-mei;LIU Yao;ZHANG Zi-xiang(Postgraduate Student,Grade 2015,Gannan Medical University,Ganzhou,Jiangxi 341000;The First Affiliated Hospital,Gannan Medical University,Ganzhou,Jiangxi 341000)

机构地区：[1]赣南医学院第一临床医学院,江西赣州341000 [2]赣南医学院第一附属医院,江西赣州341000

出　　处：《赣南医学院学报》2018年第1期94-98,共5页JOURNAL OF GANNAN MEDICAL UNIVERSITY

摘　　要：乙型肝炎病毒(Hepatitis B virus,HBV)感染呈世界性流行,是引起慢性肝炎、肝硬化、肝癌的主要原因,然而,当前的干扰素与核苷和核苷酸类药物等HBV治疗药物不能显著提高功能性治愈的比例。随着对HBV感染宿主细胞过程不断深入的了解,针对上述过程中不同的作用靶点,对抗HBV新药的研发有了很大的进展,本文将主要对新药的研究进行简要总结。Hepatitis B virus infection is a worldwide epidemic and is the main cause of chronic Hepatitis,liver cirrhosis and liver cancer.However,the current HBV therapeutic drugs such as interferons and nucleoside and nucleotides can not significantly improve the functional cure ratio.With the deepening understanding of the process of HBV infected host cells,the research and development of new drugs against HBV aiming at different targets has been made great progress.This article will briefly summarize the research of new drugs.

关 键 词：慢性乙型肝炎 抗病毒药物 

分 类 号：R512.62[医药卫生—内科学]